UPDATE: Canaccord Genuity Starts Vical (VICL) at Buy, promise of Allovectin and DNA vaccine
Tweet Send to a FriendGet Alerts VICL Hot Sheet
Price: $3.59 +0.56%
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VICL Now!
(Updated - September 21, 2012 10:25 AM EDT)
Canaccord Genuity initiates coverage on Vical (NASDAQ: VICL) Friday with a Buy rating and price target of $7 citing the on promise of Allovectin and its DNA vaccine platform.
"We expect widespread use in unresectable melanoma given Allovectin's clean safety profile and ease of use. We see blockbuster potential for CMV franchise (CyMVectin and out-licensed TransVax) given unmet need in large populations," analyst Ritu Baral said.
Pivotal Allovectin melanoma data expected by YE12. The firm predicts: success in 1˚ endpoint but survival, FDA's key endpoint, is the challenge. All signs point to Allovectin being safe, active and durable. Ph1 & 2 data show evidence of clinical activity (T cell infiltration of lesions, responses in non-injected tumors, vitiligo). We think Ph3 patient set (Stage 3/4 chemonaive patients) will show a higher response versus chemotherapy arm."
For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.
Shares of Vical closed at $4.23 yesterday, with a 52 week range of $2.22-$4.82.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Canaccord Genuity initiates coverage on Vical (NASDAQ: VICL) Friday with a Buy rating and price target of $7 citing the on promise of Allovectin and its DNA vaccine platform.
"We expect widespread use in unresectable melanoma given Allovectin's clean safety profile and ease of use. We see blockbuster potential for CMV franchise (CyMVectin and out-licensed TransVax) given unmet need in large populations," analyst Ritu Baral said.
Pivotal Allovectin melanoma data expected by YE12. The firm predicts: success in 1˚ endpoint but survival, FDA's key endpoint, is the challenge. All signs point to Allovectin being safe, active and durable. Ph1 & 2 data show evidence of clinical activity (T cell infiltration of lesions, responses in non-injected tumors, vitiligo). We think Ph3 patient set (Stage 3/4 chemonaive patients) will show a higher response versus chemotherapy arm."
For an analyst ratings summary and ratings history on Vical click here. For more ratings news on Vical click here.
Shares of Vical closed at $4.23 yesterday, with a 52 week range of $2.22-$4.82.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- Ladenburg Thalmann Starts UIL Holdings (UIL) at Neutral
- Credit Suisse Starts New Residential Investment (NRZ) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
